Author | Eduardo Diaz-rubio, MD, PhD

Articles

UFT Plus or Minus Calcium Folinate for Metastatic Colorectal Cancer in Older Patients

July 01, 1999

ByEduardo Diaz-rubio, MD, PhD

Javier Sastre, MD, PhD

Albert Abad, MD, PhD

Matilde Navarro, MD

Enrique Aranda, MD, PhD

Alfredo Carrato, MD, PhD

Manuel Gallén, MD

Eugenio Marcuello, MD

Julio Rifá, MD

Tomeu Massuti, MD

Andrés Cervantes, MD, PhD

Antonio Antón, MD, PhD

Carlos Fernandez-martos, MD

Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal

UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support

September 02, 1997

ByMiguel Martin, MD, PhD

Antonio Casado, MD

José Antonio López-Martin, MD

Alvaro Rodriguez-lescure, MD

Yago Nieto, MD

Francisco Ayala, MD

Eduardo Diaz-rubio, MD, PhD

Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral

Neoadjuvant Therapy With Cisplatin/Fluorouracil vs Cisplatin/UFT in Locally Advanced Squamous Cell Head and Neck Cancer

September 02, 1997

ByJ. L. González-Larriba, MD, PhD

I. Garcia Carbonero, MD

J. Sastre Valera, MD, PhD

P. Perez Segura, MD

Eduardo Diaz-rubio, MD, PhD

This study compared the activity and toxicity of fluorouracil (5-FU)/cisplatin with the combination tegafur and uracil (UFT)/cisplatin in the neoadjuvant treatment of locally advanced-stage III or IV (M0)-head and neck

UFT Plus Oral Folinic Acid as Therapy for Metastatic Colorectal Cancer in Older Patients

September 02, 1997

ByAlbert Abad, MD, PhD

Cristina Martín, MD

Matilde Navarro, MD

Javier Sastre, MD, PhD

Eduardo Diaz-rubio, MD, PhD

Eugenio Marcuello, MD

Enrique Aranda, MD, PhD

Manuel Gallén, MD

Carlos Fernandez-martos, MD

The oral fluoropyrimidines have proved to be active in colorectal cancer in Japan and, recently, in the United States and Europe. Continuous oral administration simulates protracted fluorouracil (5-FU) continuous